Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q86WD1 (
CREB3L2-PPARgamma
)
1
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The discovery of gene fusion mutations, particularly in leukemia, has consistently identified new
cancer
pathways and led to molecular diagnostic assays and molecular-targeted chemotherapies for
cancer
patients. Here, we report our discovery of a novel
CREB3L2-PPARgamma
fusion mutation in thyroid carcinoma with t(3;7)(p25;q34), showing that a family of somatic PPARgamma fusion mutations exist in thyroid cancer. The
CREB3L2-PPARgamma
fusion encodes a
CREB3L2-PPARgamma
fusion protein that is composed of the transactivation domain of CREB3L2 and all functional domains of PPARgamma1.
CREB3L2-PPARgamma
was detected in <3% of thyroid follicular carcinomas. Engineered overexpression of
CREB3L2-PPARgamma
induced proliferation by 40% to 45% in primary human thyroid cells, consistent with a dominant oncogenic mechanism. Wild-type CREB3L2 was expressed in the thyroid as a bZIP transcription factor with a transmembrane domain that has flanking S1P and S2P proteolytic cleavage sites. Native CREB3L2 was cleaved to nuclear CREB3L2 by regulated intramembrane proteolysis in normal thyroid cells that expressed the S1P and S2P proteases. Nuclear CREB3L2 stimulated transcription 8-fold from the EVX1 cyclic AMP (cAMP) response element in the absence of cAMP, whereas
CREB3L2-PPARgamma
inhibited transcription 6-fold from EVX1 in the same experiments.
CREB3L2-PPARgamma
also inhibited 4-fold the expression of thyroglobulin, a native cAMP-responsive gene, in primary thyroid cells treated with thyroid-stimulating hormone. Our findings identify a novel
CREB3L2-PPARgamma
gene fusion mutation in thyroid carcinoma and reveal a thyroid signaling pathway that is regulated by intramembrane proteolysis and disrupted in
cancer
.
Cancer
Res 2008 Sep 01
PMID:CREB3L2-PPARgamma fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. 1875 31